• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

State Coverage and Reimbursement of Antiobesity Medications in Medicaid.

作者信息

Liu Benjamin Y, Rome Benjamin N

机构信息

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

JAMA. 2024 Apr 9;331(14):1230-1232. doi: 10.1001/jama.2024.3073.

DOI:10.1001/jama.2024.3073
PMID:38483403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10941017/
Abstract
摘要

相似文献

1
State Coverage and Reimbursement of Antiobesity Medications in Medicaid.医疗补助计划中抗肥胖药物的州覆盖范围及报销情况
JAMA. 2024 Apr 9;331(14):1230-1232. doi: 10.1001/jama.2024.3073.
2
GLP-1 Medication Use for Type 2 Diabetes Has Soared.用于2型糖尿病的胰高血糖素样肽-1（GLP-1）药物的使用量激增。
JAMA. 2024 Sep 24;332(12):952-953. doi: 10.1001/jama.2024.18219.
3
How Will Repealing the ACA Affect Medicaid? Impact on Health Care Coverage, Delivery, and Payment.废除《平价医疗法案》将如何影响医疗补助计划？对医疗保健覆盖范围、提供和支付的影响。
Issue Brief (Commonw Fund). 2017 Mar;8:1-10.
4
Medicaid and indigent care issue brief: Medicaid: provider reimbursement.医疗补助与贫困医疗问题简报：医疗补助：对医疗服务提供者的偿付
Issue Brief Health Policy Track Serv. 2000 Jun 1:1-15.
5
Are You Following Your Reimbursement "Playbook"?你是否遵循报销“手册”？
Adv Skin Wound Care. 2019 Jul;32(7):295-296. doi: 10.1097/01.ASW.0000559955.31282.fd.
6
Medicaid and indigent care issue brief: Medicaid: provider reimbursement.医疗补助与贫困医疗问题简报：医疗补助：医疗服务提供者报销
Issue Brief Health Policy Track Serv. 2000 Jul 1:1-15.
7
Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2004.医疗补助与贫困医疗问题简报：医疗补助：医疗服务提供者报销：2004年年终报告
Issue Brief Health Policy Track Serv. 2004 Dec 31:1-24.
8
State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.2012 年至 2015 年，州医疗补助计划对慢性丙型肝炎感染药物的报销情况。
Value Health. 2018 Jun;21(6):692-697. doi: 10.1016/j.jval.2017.09.011. Epub 2017 Nov 7.
9
Changes to Medicare, Medicaid Coverage Could Cause Thousands of Deaths.医疗保险和医疗补助覆盖范围的变化可能导致数千人死亡。
JAMA. 2024 Jun 11;331(22):1884. doi: 10.1001/jama.2024.8426.
10
Dependent Coverage under the ACA and Medicaid Coverage for Childbirth.《平价医疗法案》下的受抚养人保险范围及分娩的医疗补助保险范围
N Engl J Med. 2016 Jan 14;374(2):194-6. doi: 10.1056/NEJMc1507847.

引用本文的文献

1
Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.美国医疗补助计划中抗肥胖药物的支出、使用情况及价格趋势：1999年至2023年的实证分析
Front Med (Lausanne). 2025 Jul 16;12:1537181. doi: 10.3389/fmed.2025.1537181. eCollection 2025.
2
Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US.获得可负担的GLP-1肥胖症药物：美国指导市场行动和政策解决方案的策略
J Comp Eff Res. 2025 Sep;14(9):e250083. doi: 10.57264/cer-2025-0083. Epub 2025 Jul 11.
3
Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?肥胖症的药物治疗：我们是否准备好选择、定制和联合药物治疗以实现更宏伟的目标？
Front Endocrinol (Lausanne). 2025 Jun 18;16:1569468. doi: 10.3389/fendo.2025.1569468. eCollection 2025.
4
Comparing clinical practice habits among obesity medicine physicians by patient, physician and clinic factors.通过患者、医生和诊所因素比较肥胖医学医生的临床实践习惯。
Obes Pillars. 2025 Jan 7;13:100157. doi: 10.1016/j.obpill.2025.100157. eCollection 2025 Mar.
5
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.美国超重或肥胖成年人中双重标记GLP-1受体激动剂的停药与重新开始使用情况
JAMA Netw Open. 2025 Jan 2;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349.
6
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.用于减肥的复方胰高血糖素样肽-1受体激动剂：科罗拉多州的直接面向消费者的市场。
J Pharm Policy Pract. 2024 Dec 24;18(1):2441220. doi: 10.1080/20523211.2024.2441220. eCollection 2025.
7
Anti-obesity medication patients' self-reported food savings versus the cost of such medicines.抗肥胖药物治疗患者自我报告的食物节省情况与此类药物成本的对比。
Int J Obes (Lond). 2025 Mar;49(3):532-535. doi: 10.1038/s41366-024-01708-y. Epub 2024 Dec 29.
8
Longitudinal policy surveillance of state obesity legislation in California, 1999-2020.1999-2020 年加利福尼亚州肥胖立法的纵向政策监测。
BMC Public Health. 2024 Nov 6;24(1):3064. doi: 10.1186/s12889-024-20557-y.
9
Applying an Equity Lens to Pediatric Obesity: Clinical, Environmental, and Policy Considerations for Clinicians.将公平视角应用于儿科肥胖：临床、环境和政策方面的考虑因素。
Pediatr Clin North Am. 2024 Oct;71(5):805-818. doi: 10.1016/j.pcl.2024.07.001. Epub 2024 Aug 8.
10
Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication.医保覆盖范围解读：一项定性研究，探讨保险公司停止承保抗肥胖药物政策的感知影响。
Obes Pillars. 2024 Jul 22;11:100120. doi: 10.1016/j.obpill.2024.100120. eCollection 2024 Sep.